Metastatic Prostate Cancer Market Research Report – Segmentation by Product Type (Injections, Liquid dosage form, Solid dosage form, Tablet, Capsule, Semisolid dosage form, Cream, Oral); By Route of Administration (Injections, Liquid dosage form, Solid dosage form, Tablet, Capsule, Semisolid dosage form, Cream, Oral); By Treatment (Hormonal therapy, Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Androgen synthesis inhibitors, Androgen receptor blockers, Biologic therapy, Chemotherapy, Systemic chemotherapy, Regional chemotherapy, Targeted therapy, Monoclonal antibody, Small molecule drugs, Immunotherapy, Immune checkpoint inhibitors, Monoclonal antibodies, Immune system modulators);and Region; - Size, Share, Growth Analysis | Forecast (2024– 2030)
Published: 2024 - January
Report Code: IM-16165
Format:
Region: Global
Chapter 1. Global Metastatic Prostate Cancer Market– Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Metastatic Prostate Cancer Market – Executive Summary
2.1. Market Size & Forecast – (2024 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. Global Metastatic Prostate Cancer Market– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. Global Metastatic Prostate Cancer Market - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Metastatic Prostate Cancer Market- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Metastatic Prostate Cancer Market– By Product Type
6.1. Introduction/Key Findings
6.2. Injections
6.3. Liquid dosage form
6.4. Solid dosage form
6.5. Tablet
6.6. Capsule
6.7. Semisolid dosage form
6.8. Cream
6.9. Oral
6.10. Y-O-Y Growth trend Analysis By Product Type
6.11 . Absolute $ Opportunity Analysis By Product Type , 2024-2030
Chapter 7. Global Metastatic Prostate Cancer Market– By Route of Administration
7.1. Introduction/Key Findings
7.2. Oral
7.3. Parenteral route
7.4. Intravenous
7.5. Intrathecal
7.6. Intraperitoneal
7.7. Intra-arterial
7.8. Topical
7.9. Y-O-Y Growth trend Analysis By Route of Administration
7.10. Absolute $ Opportunity Analysis By Route of Administration , 2024-2030
Chapter 8. Global Metastatic Prostate Cancer Market– By Treatment
8.1. Introduction/Key Findings
8.2 Hormonal therapy
8.3. Luteinizing Hormone-Releasing Hormone (LHRH) agonists
8.4. LHRH antagonists
8.5. Androgen synthesis inhibitors
8.6. Androgen receptor blockers
8.7. Biologic therapy
8.8. Chemotherapy
8.9. Systemic chemotherapy
8.10. Regional chemotherapy
8.11. Targeted therapy
8.12. Monoclonal antibody
8.13. Small molecule drugs
8.14. Immunotherapy
8.15. Immune checkpoint inhibitors
8.16. Monoclonal antibodies
8.17. Immune system modulators
818. Y-O-Y Growth trend Analysis Treatment
8.19. Absolute $ Opportunity Analysis Treatment , 2024-2030
Chapter 9. Global Metastatic Prostate Cancer Market, By Geography – Market Size, Forecast, Trends & Insights
9.1. North America
9.1.1. By Country
9.1.1.1. U.S.A.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. By Product Type
9.1.3. By Route of Administration
9.1.4. By Treatment
9.1.5. Countries & Segments - Market Attractiveness Analysis
9.2. Europe
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Germany
9.2.1.3. France
9.2.1.4. Italy
9.2.1.5. Spain
9.2.1.6. Rest of Europe
9.2.2. By Product Type
9.2.3. By Route of Administration
9.2.4. By Treatment
9.2.5. Countries & Segments - Market Attractiveness Analysis
9.3. Asia Pacific
9.3.2. By Country
9.3.2.2. China
9.3.2.2. Japan
9.3.2.3. South Korea
9.3.2.4. India
9.3.2.5. Australia & New Zealand
9.3.2.6. Rest of Asia-Pacific
9.3.2. By Product Type
9.3.3. By Route of Administration
9.3.4. By Treatment
9.3.5. Countries & Segments - Market Attractiveness Analysis
9.4. South America
9.4.3. By Country
9.4.3.3. Brazil
9.4.3.2. Argentina
9.4.3.3. Colombia
9.4.3.4. Chile
9.4.3.5. Rest of South America
9.4.2. By Product Type
9.4.3. By Route of Administration
9.4.4. By Treatment
9.4.5. Countries & Segments - Market Attractiveness Analysis
9.5. Middle East & Africa
9.5.4. By Country
9.5.4.4. United Arab Emirates (UAE)
9.5.4.2. Saudi Arabia
9.5.4.3. Qatar
9.5.4.4. Israel
9.5.4.5. South Africa
9.5.4.6. Nigeria
9.5.4.7. Kenya
9.5.4.8. Egypt
9.5.4.9. Rest of MEA
9.5.2. By Product Type
9.5.3. By Route of Administration
9.5.4. By Treatment
9.5.5. Countries & Segments - Market Attractiveness Analysis
Chapter 10. Global Metastatic Prostate Cancer Market– Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1 Novartis AG
10.2. AstraZeneca
10.3. Pfizer Inc.
10.4. Merck & Co., Inc.
10.5. Bayer AG
10.6. Sanofi
10.7. Bristol-Myers Squibb Company
10.8. AbbVie Inc.
10.9. Hoffmann-La Roche Ltd.
10.10. Ipsen Biopharmaceuticals, Inc.
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Metastatic Prostate Cancer Market was valued at USD 6.70 billion in 2023 and is projected to reach a market size of USD 11.86 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 8.5%.
The increase in prostate cancer cases. Secondly, the aging population are market drivers for metastatic Prostate Cancer
Based on Route of Administration, the Metastatic Prostate Cancer Market is segmented into Oral, Intravenous, Intramuscular, Parental, Intrathecal, Topical
. North America is the most dominant region for the Metastatic Prostate Cancer Market
Johnson & Johnson Private Limited, Novartis Ag, Pfizer, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC., and Genentech, Inc. are the key players operating in the Metastatic Prostate Cancer Market.
